Conclusions
cardiovascular death
HFrEF patients on optimal medical therapy did not benefit from extended follow-up in a specialized HF clinic. The risk of HF hospitalization and cardiovascular death, and adherence to the neurohormonal blockade, did not differ between patients followed in an HFC compared to PC. Given the high HF hospitalization and mortality rates, our results underscore the need for the development of improved monitoring programs including new technologies to improve outcomes for patients on guideline-directed therapy.